A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.
Advanced Solid Tumors
BIOLOGICAL: mRNA-4106|BIOLOGICAL: Nivolumab/Relatlimab
Number of Participants With Dose Limiting Toxicities (DLTs), For Arm 1: Days 1-21 and Arm 2: Days 1-28|Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest, Up to 2 years
The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.